Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/37605
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAbd Rahman R.en
dc.contributor.authorDeKoninck P.en
dc.contributor.authorMurthi P.en
dc.contributor.authorWallace E.M.en
dc.date.accessioned2021-05-14T12:48:04Zen
dc.date.available2021-05-14T12:48:04Zen
dc.date.copyright2018en
dc.date.created20180205en
dc.date.issued2018-02-05en
dc.identifier.citationJournal of Maternal-Fetal and Neonatal Medicine. 31 (4) (pp 525-529), 2018. Date of Publication: 16 Feb 2018.en
dc.identifier.issn1476-7058en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/37605en
dc.description.abstractIn this review, we discuss the potential use of antimalarial drugs as an adjuvant therapy for preeclampsia, focusing on the mechanisms of action of this class of drugs in the context of preeclampsia. In particular, hydroxychloroquine has been shown to have various beneficial effects on patients with systemic lupus erythematosus. There are several pathways targeted by the antimalarial drugs that are similar to the pathophysiology of preeclampsia and hence offering opportunities to develop novel therapies to treat the disease. Given the safety profile of hydroxychloroquine in pregnancy, there is merit in exploring the efficacy of this drug as an adjuvant therapy in women with early onset preeclampsia.Copyright © 2017 Informa UK Limited, trading as Taylor & Francis Group.en
dc.languageEnglishen
dc.languageenen
dc.publisherTaylor and Francis Ltd (E-mail: healthcare.enquiries@informa.com)en
dc.relation.ispartofJournal of Maternal-Fetal and Neonatal Medicineen
dc.titleTreatment of preeclampsia with hydroxychloroquine: a review.en
dc.typeReviewen
dc.identifier.affiliationObstetrics and Gynaecology (Monash Women's)-
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/14767058.2017.1289511en
dc.publisher.placeUnited Kingdomen
dc.identifier.orcidMurthi, Padma; ORCID: http://orcid.org/0000-0003-2535-5134 Wallace, Euan M.; ORCID: http://orcid.org/0000-0002-4506-5233en
dc.identifier.pubmedid28142291 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28142291]en
dc.identifier.source620338254en
dc.identifier.institution(Abd Rahman) Department of Obstetrics and Gynecology, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia (DeKoninck, Murthi, Wallace) Department of Medicine, School of Clinical Sciences, Monash University, Monash Medical Centre, Clayton, VIC, Australia (Abd Rahman, Wallace) The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australiaen
dc.description.addressE.M. Wallace, Department of Obstetrics and Gynecology, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia. E-mail: euan.wallace@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2018 Elsevier B.V., All rights reserved.en
dc.subect.keywordsantimalarial drugs mechanisms of action Preeclampsiaen
dc.identifier.authoremailWallace E.M.; euan.wallace@monash.eduen
dc.description.grantNo: 1069364 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australiaen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Articles
Show simple item record

Page view(s)

16
checked on Sep 11, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.